BLLSF (BioLight Life Sciences) Short-Term Debt: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLLSF BioLight Life Sciences Ltd BLLSF
16 GF Score
Price $0.09
! 3 Warning Signs
View Full Analysis

What is BioLight Life Sciences Short-Term Debt?

BioLight Life Sciences BLLSF 16 Short-Term Debt is $0.00 Mil as of Dec. 2025. GuruFocus rates BLLSF with a GF Score™ of 16/100. The stock has 3 warning signs investors should review.

BioLight Life Sciences's Short-Term Debt for the quarter that ended in Dec. 2025 was $0.00 Mil.

BioLight Life Sciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

BioLight Life Sciences Short-Term Debt Related Terms

BioLight Life Sciences Short-Term Debt Historical Data

* Premium members only.

The historical data trend for BioLight Life Sciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLight Life Sciences Short-Term Debt Chart

BioLight Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BioLight Life Sciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BLLSF
16GF Score
BioLight Life Sciences Ltd BLLSF
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
BioLight Life Sciences (BLLSF) has a Short-Term Debt of $0.00 Mil as of Dec. 2025.
Is BioLight Life Sciences' Short-Term Debt too high?
BioLight Life Sciences' current Short-Term Debt is $0.00 Mil. Overall, BioLight Life Sciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does BioLight Life Sciences' Short-Term Debt compare to VRTX and REGN?
BioLight Life Sciences' Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. BioLight Life Sciences's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLight Life Sciences stock overvalued right now?
BioLight Life Sciences (BLLSF) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. BioLight Life Sciences' overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For BioLight Life Sciences (BLLSF), the current Short-Term Debt is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioLight Life Sciences Business Description

Other Exchanges BOLT:Israel
Address Aba Hillel Silver 12, 11 floor, Ramat Gan, ISR, 5250606
BioLight Life Sciences Ltd is an emerging ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.
16GF Score

Get the complete analysis for BLLSF

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.09
Price